A new biological home
for the [European] gut.
Tiny Tribes is the EU-native synbiotic platform — pre + pro + post in one system built around microbiome testing and a sequenced gut journey across four phases.
Most gut brands sell a product.
Tiny Tribes sells a programme.
The European gut market is mature and crowded — but no single brand has built the integrated synbiotic system. OMNi-BiOTiC (Austria) leads on clinical science with twelve targeted SKUs. Kijimea (Germany) owns pharmacy-clinical credibility. Symprove (UK) sells the gut treatment course. Cuure (Paris) has cracked personalised DTC subscription. ZOE (UK) now combines test + app + Daily30+ wholefood prebiotic. Atlas Biomed has the test. None offers a sequenced four-phase synbiotic protocol — pre + pro + post strains rotated quarterly, driven by individual microbiome test results. That specific intersection is Tiny Tribes' lane.
"An EU-native gut subscription built on a sequenced four-phase ingredient roadmap and a partner-network loop (InnerBuddies + Noory + Novonesis + Maastricht). The model is replicable; what compounds is execution, clinical data, and EU regulatory fluency."
"Your gut, sequenced. Most gut supplements give you the same capsule for three years. Tiny Tribes rotates through four ingredient phases tuned to where your microbiome actually is."
"Test-personalised probiotics exist (Sun Genomics, Biohm, Viome). Synbiotic subscriptions exist (Cuure, Ritual, Seed). Phase rotation, EU compliance, Mediterranean voice — that combination is what's missing."
What makes Tiny Tribes structurally different.
What's inside this brand book.
Eight chapters covering the full Tiny Tribes thesis. Use the tabs above to navigate.
| # | Chapter | What you'll find |
|---|---|---|
| 02 | Who / Why / How | The customer, the thesis, and the test → app → product → re-test loop. |
| 03 | The Name | Why "Tiny Tribes" — bacterial communities, plain English, defensible territory. Naming logic in full. |
| 04 | Product Architecture | Three-tier subscription system — Foundation €79, Complete €89, Intelligence €119. |
| 05 | Ingredient Strategy | The four-phase prebiotic + probiotic + postbiotic roadmap. |
| 06 | Competitive Landscape | 30+ EU and global competitors mapped across direct, indirect, and gateway tiers. |
| 07 | Marketing Angles | Six campaign concepts including the GLP-1 companion play. |
| 08 | Brand Identity | Logo, palette, typography, voice — full visual system. |
| 09 | Plan & Financials | Phased implementation, unit economics, ARR trajectory. |
Who it's for. Why it works. How it closes the loop.
Most gut brands sell a bottle and hope. Tiny Tribes sells a closed loop: a real customer, a defensible thesis, and an operational system that proves itself with every cohort. This chapter is the strategy in three parts — the buyer, the bet, and the machine that makes the bet pay off.
The Tiny Tribes subscriber.
Tiny Tribes is built for a specific European buyer. Not the mass-market yoghurt drinker, not the practitioner-only IBS patient, not the US biohacker. Someone in between — and that segment is large, underserved, and growing.
Three buyer archetypes.
The four-part thesis.
Tiny Tribes only makes sense if four things are simultaneously true. They are. That is the bet.
European gut health is at an inflection.
The EU probiotic supplement market is €15bn in 2026, growing 4.8–7.3% CAGR, with Spain (10.1%) and Italy (9.8%) accelerating fastest. 25% of UK adults already consume probiotic drinks weekly (YouGov 2025). 40% of EU adults report regular digestive discomfort. The category is no longer being created — it is being upgraded.
The synbiotic + phase rotation + test-personalised intersection is empty.
OMNi-BiOTiC has the targeted-condition science. Cuure has the personalised box and a synbiotic. Symprove has the course. ZOE now has the test, app, and Daily30+ wholefood prebiotic. None offers a sequenced four-phase synbiotic protocol — pre + pro + post strains rotated quarterly — driven by individual microbiome test results. That specific intersection is Tiny Tribes' lane, and the closer ZOE moves into the broader space, the more defensible that specificity becomes.
EU-native compliance compounds advantage over time.
EFSA's restrictive position on the word "probiotic" forces every brand into either non-compliant US-style copy or vague "live and active bacteria supplement" language. Brands launched before regulatory clarification carry compliance debt that takes years to fix. Tiny Tribes launches with EFSA-defensible copy from Day 0 — and that gap widens with every new claim restriction Brussels publishes.
Every subscriber improves the protocol for the next.
A subscriber on the Intelligence tier produces two microbiome readings per year. 5,000 subscribers = 10,000 paired data points in Year 1 — enough to refine phase ordering and validate the protocol; not yet enough to publish or claim a moat. By Year 3, at 30,000+ paired tests, the dataset supports academic collaboration and meaningful R&D leverage. The product gets sharper as the company grows. The compounding loop is real; the timeline must be honest.
The closed loop.
The Tiny Tribes system is not a product line. It is a five-stage operational loop. Test feeds protocol; protocol drives the app; app drives adherence; adherence produces the re-test; the re-test proves the protocol and personalises the next phase. Each stage is operationally simple. The advantage isn't that the loop is unbuildable — Sun Genomics, Thryve, ZOE all run pieces of it — but that doing it cleanly, EU-compliantly, with a sequenced ingredient roadmap, in Mediterranean voice, takes the kind of focus a generalist competitor will not bring.
Test — the baseline microbiome reading
Protocol — the phase order, tuned to the test
App — the daily layer that turns a supplement into a system
Protocol delivery — sequenced phases, monthly
Re-test — the proof, and the next personalisation
The partner network behind the loop.
Tiny Tribes is the brand, the formulation, the protocol, and the experience. Behind that surface sits a small network of specialist EU partners — each chosen for category dominance, regulatory clarity, and (where useful) future acquisition optionality. The architecture stays light; the partnerships do the heavy lifting.
- Senior microbiome researcher — PhD-level scientific authority on the protocol, future co-author on clinical publications.
- Gastroenterology clinician(s) — advisory board; lend clinical credibility to any health-related communications.
- Registered dietitian (clinical nutrition background) — real-world application, meal-planning integration with Noory, day-to-day nutrition guidance for subscribers.
- Microbiologist / formulation scientist — strain selection, bioinformatics oversight, batch QA review.
- EU food-law specialist on retainer — EFSA compliance, Novel Food applications, label review.
The pattern is consistent: pick the EU specialist already operating at scale, integrate via API or contract, brand the experience as Tiny Tribes. The subscriber sees one product. Behind it, four interlocking partners.
What's actually defensible — and what isn't.
A clear-eyed read: with current tech, the architecture is copyable. Sun Genomics, Thryve, Biohm, Viome have all run test → personalised probiotic loops for years globally. ZOE, Cuure, and Atlas Biomed run pieces of the system in Europe. Tiny Tribes' advantages are real but mostly take the form of execution moats — things a competitor could match but only with time, money, and specific choices a generalist won't make. The four below are honest about which is which.
The honest summary. Tiny Tribes' defensibility comes from being the first to combine (a) EU compliance and (b) phase rotation under (c) a credible local brand voice, then compounding through (d) clinical data over time. None of these is unfakeable. All require time, capital, and specific strategic choices to replicate. The window to lock in narrative position is 12–18 months. After that, the bet is execution speed and brand love — not architecture.
Why Tiny Tribes.
The brand name had to do four things at once: carry a legitimate biological idea, work phonetically across European languages, sit in defensible trademark territory, and open up a narrative system the rest of the brand could be built on. Tiny Tribes earns all four — and trades the cold-clinical register of most gut brands for something warmer, more human, and unmistakably ownable.
Two everyday English words that carry the biology accurately. Tiny — the microbe is microscopic, weighs less than a grain of dust, and yet runs the show. Tribes — bacterial communities are not random soup; they organise into structured consortia with territory, succession, and shared resources. Microbiologists describe gut populations in exactly these terms (community, consortium, guild). "Tribes" is the human translation of the science, not a metaphor pasted on top of it.
The four-layer test
Why this name passes.
- Biologically true. Gut microbiome ecology literally describes bacterial populations as communities and consortia. "Tribes" is the consumer-readable version of the textbook term — not a marketing stretch.
- European phonetics. Both words translate cleanly: Pequeñas Tribus · Petites Tribus · Piccole Tribù · Kleine Stämme · Kleine Stammen. Or hold the English wordmark across all markets — the lockup reads.
- Trademark territory. Clean in EUIPO classes 5 (supplements) and 29 (functional foods) against the entire EU competitive set (OMNi-BiOTiC, Symprove, Cuure, Kijimea, Bio-Kult, Optibac). One collision to manage in adjacent territory: Tiny Health, US-based, kids/family microbiome testing — addressed below.
- Owns a narrative system. Find your tribe · Build your tribe · Each tribe in its time. The four-phase sequence becomes "the four tribes": Foundation Tribe, Mediterranean Tribe, Blueprint Tribe, Origin Tribe. Packaging, app copy, content, community all flow from one idea.
The narrative architecture
Your gut is not one organism. It is roughly 100 trillion individual cells, organised into around 1,000 distinct species, clustering into a smaller number of identifiable community structures — what microbiologists call guilds, consortia, or in some recent papers, simply tribes. Each cluster has territory, behaviour, succession patterns, and a job. Some make butyrate. Some break down polyphenols. Some keep the mucin layer intact. Some quiet the immune system. When one tribe weakens, another moves in — sometimes helpfully, sometimes not.
Most supplements ignore this. They ship the same monoculture every month — Lactobacillus everywhere, Bifido everywhere, hope. Tiny Tribes is the opposite proposition: understand the tribes you have, supply the tribes you need, in the order they need to arrive. The name is the product specification.
Three tiers. One system.
Tiny Tribes sells a subscription, not a SKU. The product line is structured around three subscription tiers — Foundation, Complete, and Intelligence — each adding a layer of personalisation and clinical depth. The Synbiotic Trinity (pre + pro + post) is present in every tier; what varies is the sophistication of the protocol.
- Phase 1 prebiotic blend (Arabinoxylan + Baobab)
- Multi-strain probiotic core (10–12 strains per phase · 24 unique strains across the full 4-phase cycle)
- Postbiotic support (butyrate precursors)
- Onboarding gut journey content
- Monthly delivery, free EU shipping
- Everything in Foundation
- Quarterly phase rotation (Phases 1–4)
- Olive Pomace + Pomegranate Peel from Phase 2
- Akkermansia muciniphila when EU-approved
- Subscriber-only science briefings
- Everything in Complete
- Quarterly InnerBuddies sequencing
- Personalised phase ordering
- HMO premium upgrade in Phase 3
- Direct nutritionist consultation (1×/quarter)
The Synbiotic Trinity — what's actually in every tier
No proprietary blends. Every ingredient declared with its dose. EFSA-compliant claim language only. This is the structural commitment that separates Tiny Tribes from AG1, IM8, and the rest of the greens-with-probiotics category.
Why 24 sequenced strains beats 25 simultaneous ones.
The supplement industry uses total strain count as a proxy for quality. Cuure's FS-3B leads with 25 strains at 50B CFU. Seed DS-01 uses 24 strains at 53.6B AFU. Both are excellent products — but both deliver their full strain library simultaneously. This is where the science diverges from the marketing.
A landmark 2018 study in Cell[1] found that simultaneously administered multi-strain cocktails produced poor mucosal colonisation in a significant subset of subjects — not because the strains were bad, but because competitive exclusion between co-administered strains reduces individual colonisation rates by up to 40%. A crowded environment benefits the most aggressive colonisers and disadvantages slower-establishing species, regardless of how clinically validated those species are individually. A companion 2018 Cell paper[2] confirmed that standard multi-strain probiotic delivery actively impaired microbiome recovery in post-antibiotic patients, compared to autologous FMT — again attributing the effect to ecological competition between strains rather than any individual strain failure.
Tiny Tribes' response is architectural. 10–12 strains per phase · 24 unique strains across the full cycle · four sequential cohorts, each given 90 days to establish before the next arrives. This is not a compromise on diversity — it is a more sophisticated delivery model that works with gut colonisation ecology rather than against it. The result is a protocol with greater individual strain colonisation probability, measurable diversity improvement over time, and a built-in re-test loop (Intelligence tier) that proves it.
- [1] Zmora N. et al. (2018). Personalized Gut Mucosal Colonization Resistance to Empiric Probiotics Is Associated with Unique Host and Microbiome Features. Cell, 174(6), 1388–1405. doi.org/10.1016/j.cell.2018.08.041
- [2] Suez J. et al. (2018). Post-Antibiotic Gut Mucosal Microbiome Reconstitution Is Impaired by Probiotics and Improved by Autologous FMT. Cell, 174(6), 1406–1423. doi.org/10.1016/j.cell.2018.08.047
- [3] Tannock G.W. et al. (2000). Analysis of the fecal microflora of human subjects consuming a probiotic product containing L. rhamnosus DR20. Applied & Environmental Microbiology, 66(6), 2578–2588. doi.org/10.1128/AEM.66.6.2578-2588.2000
Reference numbering is global. Full bibliography in context/rnd/09-references-library.md.
The compounding data and what it actually buys.
The Intelligence tier is more than a personalisation feature — it is a research engine. Every subscriber who tests pre- and post-protocol generates a real data point. Year 1, with ~5,000 paired tests, is enough to refine phase ordering and validate the protocol clinically. Year 3, at 30,000+ paired tests, is when this becomes a genuine R&D asset and supports academic publication. ZOE, Atlas Biomed, and Sun Genomics all have larger or older datasets globally — the Tiny Tribes position is to build the largest EU-native, synbiotic-protocol-paired longitudinal dataset, which is a narrower and more credible claim. The point is not to claim a moat that already exists, but to compound one over time.
More strains is not better.
Sequenced strains are.
Tiny Tribes ships 10–12 strains per phase — 24 unique across the full cycle, delivered in four sequential 90-day cohorts. The difference is not strain count, it is delivery architecture. And the architecture is grounded in 2018 peer-reviewed gut microbiome research[1][2] that the supplement industry has not yet caught up to.
What our competitor review told us
Before we set our own protocol, we reviewed the leading European and global synbiotic brands. The consistent pattern: ship as many strains as possible in a single daily dose — twenty-five strains, fifty billion CFU, the higher the better. The implicit message to the consumer: more strains = more benefit. We came away from that review convinced this approach is incomplete in a way that quietly makes high-strain products worse, not better. Here is why we chose to do it differently — and the science that grounded the decision.
The 2018 Cell papers — and what they showed
Two landmark papers in Cell (one of biology's highest-impact journals) fundamentally changed how serious gut microbiome scientists think about probiotic delivery.
Subjects given an 11-strain probiotic cocktail showed highly variable mucosal colonisation measured by endoscopy. Most subjects showed little colonisation of the introduced strains. The mechanism: strain-on-strain competition reduces individual colonisation rates by up to 40%.
In post-antibiotic patients, the standard probiotic cocktail actively impaired microbiome reconstitution compared to autologous FMT and untreated controls. More strains, delivered simultaneously, slowed recovery rather than accelerating it.
The four mechanisms of strain competition
When many strains are introduced simultaneously into a finite gut ecosystem, four competitive dynamics suppress colonisation:
The mucosal surface has a finite number of adhesion sites. Strains with the strongest mucin-binding pili (like L. rhamnosus GG's SpaCBA pilus) win the available real estate. Weaker adherers wash through.
Generalist strains with broad metabolic repertoires consume the available prebiotic fibre first. Specialists — including the most clinically interesting strains like B. infantis EVC001 — starve.
Many probiotic strains produce bacteriocins — antimicrobial peptides that inhibit other bacteria, including other probiotic strains. L. salivarius UCC118's ABP-118 suppresses many Gram-positives. Strain combinations are not always synergistic.
The gut immune system has a limited capacity to tolerate novel antigens simultaneously. Excessive simultaneous strain introduction can trigger broad downregulation, suppressing colonisation of the entire cohort.
The garden metaphor
Think of the gut as a garden. The conventional approach plants two dozen seedlings in the same flowerbed on day one — all competing for the same light, water, and soil nutrients. Some thrive, most struggle. Tiny Tribes plants in succession: primary cover crops first to fix the soil; specialised crops once the foundation is laid; pollinators next; perennials last to sustain the system long-term. Sequential planting outperforms simultaneous planting because each cohort prepares the substrate for what comes next.
The Tiny Tribes architecture — visualised
10 strains · Broad-spectrum Lactobacillus + Bifidobacterium. Barrier repair. Mucin restoration.
Feed: Arabinoxylan + Baobab
10 strains · Polyphenol metabolisers + Akkermansia muciniphila MucT. Diversity boost.
Feed: Olive pomace + Pomegranate
12 strains · HMO-matched specialists led by B. infantis EVC001. Deep personalisation.
Feed: HMOs (2'-FL + LNnT)
10 strains · Psychobiotics. L. rhamnosus JB-1 + B. longum 1714. Gut-brain.
Feed: Multi-mushroom β-glucans
L. rhamnosus GG · L. acidophilus NCFM · B. lactis Bl-04 · L. reuteri DSM 17938 · B. bifidum MIMBb75
Why this order — not random
The four phases are not interchangeable. The order matters for ecological reasons.
- Foundation → Mediterranean. Barrier integrity must precede polyphenol metabolism. Akkermansia muciniphila[23] (Phase 2 headline) requires a healthy mucin layer to feed on. Delivering Akkermansia first, before the mucin layer has been rebuilt by Phase 1, gives it nothing to consume.
- Mediterranean → Blueprint. Diversity must be in place before precision substrates (HMOs) are useful. HMOs are selective — they feed B. infantis[20] specifically. Without diversity baseline, you create monoculture risk.
- Blueprint → Origin. Gut-brain strains (L. rhamnosus JB-1[5], B. longum 1714[6]) require a functioning barrier (Phase 1), diverse community (Phase 2), and high SCFA production (Phase 3) to deliver psychobiotic effects. They go last because they depend on everything that came before.
The compounding consequence
Rotation isn't only a colonisation argument. It is also the data argument. After 12 months, an Intelligence-tier subscriber has been through all four phases with paired pre- and post-cycle microbiome tests. The Tiny Tribes dataset records: which phases produced the biggest shifts for this individual, which strains were most retained, which phase orderings worked better for which microbiome starting profiles. A static multi-strain capsule cannot generate this data — it ships the same formula every month and never knows what is working for whom. Tiny Tribes tells you, strain by strain, what your gut actually responded to.
The supplement industry sells probiotic strain count as a proxy for quality. Peer-reviewed gut microbiome research[1][2] shows simultaneous multi-strain delivery triggers competitive exclusion, with individual strain colonisation rates reduced by up to 40%. Tiny Tribes delivers 24 unique strains across four sequential 90-day phases. Each phase prepares the substrate for the next. Each strain gets room to establish. Each subscriber generates data on what worked for them. This is not marketing positioning — it is gut ecology, made commercial.
- [1] Zmora N. et al. (2018). Personalized Gut Mucosal Colonization Resistance to Empiric Probiotics Is Associated with Unique Host and Microbiome Features. Cell, 174(6), 1388–1405. doi.org/10.1016/j.cell.2018.08.041
- [2] Suez J. et al. (2018). Post-Antibiotic Gut Mucosal Microbiome Reconstitution Is Impaired by Probiotics and Improved by Autologous FMT. Cell, 174(6), 1406–1423. doi.org/10.1016/j.cell.2018.08.047
- [5] Bravo J.A. et al. (2011). Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. PNAS, 108(38), 16050–16055. doi.org/10.1073/pnas.1102999108 — foundational psychobiotic paper for L. rhamnosus JB-1
- [6] Allen A.P. et al. (2016). Bifidobacterium longum 1714 as a translational psychobiotic: modulation of stress, electrophysiology and neurocognition in healthy volunteers. Translational Psychiatry, 6(11), e939. doi.org/10.1038/tp.2016.191
- [20] Turroni F. et al. (2010). Genome analysis of Bifidobacterium bifidum PRL2010 reveals metabolic pathways for host-derived glycan foraging. PNAS, 107(45), 19514–19519. doi.org/10.1073/pnas.1011100107
- [23] Cani P.D. & de Vos W.M. (2017). Next-generation beneficial microbes: The case of Akkermansia muciniphila. Frontiers in Microbiology, 8, 1765. doi.org/10.3389/fmicb.2017.01765
Reference numbering is global across all Tiny Tribes documents. Full bibliography in context/rnd/09-references-library.md.
A sequenced gut journey across four phases.
Every EU competitor sells a static SKU — the same capsule, sachet, or shot, month after month. Cuure leads with 25 strains simultaneously. Seed uses 24. But peer-reviewed research (Zmora et al., Cell 2018) shows simultaneous delivery triggers competitive exclusion between co-administered strains, reducing colonisation rates by up to 40%. Tiny Tribes delivers 24 unique strains sequenced across four phases — each cohort given 90 days to colonise before the next arrives. Not fewer strains. A smarter architecture.
Arabinoxylan + Baobab
Olive Pomace + Pomegranate Peel
Human Milk Oligosaccharides (HMOs)
Multi-Mushroom + Seagreens (post regulatory)
Premortem — what could go wrong, and how Tiny Tribes pre-empts it
| Risk | Severity | Mitigation |
|---|---|---|
| EU Health Claim Shutdown | Fatal · High | EU-compliant copy from Day 0. Approved fibre claims and olive polyphenol claim only. "Prebiotic" never used in EU marketing without specialist food law sign-off per SKU. |
| Baobab 2009 Stagnation Repeats | Fatal · Medium | Education content built before launch. Gut journey narrative embedded in acquisition, not retrofit. Physical science card with every delivery. |
| Olive Polyphenol Supply Inconsistency | High · High | Single certified olive pomace supplier with fixed QA protocols and contractual 5mg hydroxytyrosol concentration guarantee per dose. |
| Akkermansia EU Approval Delay | High · Medium | Phase 2 launchable without Akkermansia using olive + pomegranate alone. Akkermansia treated as bonus addition, not gating ingredient. |
| Seagreens Arsenic / Novel Food Block | Medium · High | Phase 4 deferred to Month 18+. Multi-mushroom complex sufficient on its own; seagreens added only when EU regulatory clarity arrives. |
The EU map: direct competitors, country by country.
The European probiotic supplements market is worth €15bn in 2026 and growing 4.8–7.3% annually. Germany leads at 33.7% share, France at 24.1%, with Italy and Spain accelerating fastest at 9.8% and 10.1% CAGR. Below: the EU brands Tiny Tribes will be benchmarked against — first the Tier-1 synbiotic + subscription competitors with real momentum, then country-specific leaders, then the indirect categories.
"Targeted probiotic powder sachets — 83% gut survival rate, 100+ clinical studies, 30+ years of microbiome research."
"FS-3B Tribiotic — 25 strains, 50bn CFU, pre + pro + post in one capsule. Personalised monthly box."
"Water-based live and active bacteria supplement — 94% of customers feel a difference within 12 weeks."
"K53 — 53 synergistic probiotic strains. PRO — patented B. bifidum MIMBb75 for IBS."
"The world's largest nutrition study + at-home gut microbiome test + Daily30+, a 30-plant wholefood supplement with published RCT."
"Listen to your gut — shotgun metagenomic sequencing + DNA test, ships across Europe."
"24-strain probiotic + prebiotic, 53.6 billion AFU."
"Live Akkermansia muciniphila — first strain commercialised."
"3-in-1 prebiotic, probiotic, postbiotic. Delayed-release capsule."
"Full pre + pro + post system — ranked #1 by independent dietitians."
"40,000+ custom formulations from gut sequencing."
"Baby + child + adult + pregnancy + vaginal microbiome testing. CLIA/CAP lab, 120,000+ microbes detected."
"Daily nutrient foundation — 75 ingredients in one scoop."
"14-strain capsule. The market workhorse."
"World's most researched strains, problem-specific formulas."
"Food-Grown® Multi Strain Biotic — 8 strains, 30bn CFU per capsule."
Cluster of mid-tier French DTC brands — capsule probiotics, light synbiotic claims.
German premium DTC supplement brands with probiotic + HMO ranges.
"L. reuteri DSM 17938 — among the most researched strains in the world."
EU-native microbiome testing services with subscription tracking.
German clinical-pharmacy probiotic brands — 60+ years heritage.
"Prebiotic fibre length diversity — the science says prebiotic-first."
"Daily yoghurt for gut health."
Bolt-on gut claims without clinical infrastructure or EU compliance.
"Akkermansia + Bifidobacterium for weight management."
Multi-product wellness subscriptions with probiotic SKUs.
Premium multi-product wellness brands with probiotic SKUs.
Functional dairy with probiotic claims — Mediterranean retail dominant.
Niche or freshly funded testing-first brands.
Strategic insights from the EU map
Quick-reference: EU competitive matrix
Direct subscription synbiotic competitors with real EU presence, ranked by combined threat (market position × system completeness × subscription strength).
| Brand | HQ | Pre+Pro+Post? | Subscription | Microbiome test | EU price/mo |
|---|---|---|---|---|---|
| OMNi-BiOTiC | Austria | Pre + Pro (no formal post) | Yes | No | €30–45 |
| Cuure FS-3B | France | Yes — full trio, 25 strains | Yes | Quiz only | €39.90 |
| Symprove | UK | Pro only (4 strains, liquid) | Yes (UK) | No | £49.99 |
| Kijimea K53 / PRO | Germany | Pro only (53 / 4 strains) | Yes | No | €30–40 |
| ZOE Daily30+ / App | UK | Pre only (30+ plants, wholefood) | Yes (app + product) | Yes | £25–95 |
| Atlas Biomed | UK | No product | Yes (test) | Yes | £99/3mo |
| Wild Nutrition Multi-Strain | UK | Pro only (8 strains) | Yes | No | £30–45 |
| BioGaia Gastrus | Sweden | Pro only (L. reuteri) | OTC, no DTC sub | No | €25–35 |
| Bio-Kult | UK | Pro only (14 strains) | OTC, no DTC sub | No | £15–25 |
| Optibac | UK | Pro + light pre (FOS) | Yes | No | £14–35 |
| Tiny Tribes (target) | Spain | Yes — 4 phase rotation | Yes | Yes (Intelligence tier) | €79–119 |
Six campaign concepts.
One coherent voice.
The Tiny Tribes audience is 30–55, health-conscious, EU-based, already supplementing, and looking for a specialist upgrade. The angles below approach that audience from six different psychological doors — each resolving back to the same product truth.
"The root cause nobody told you about"
Most people treat obesity, fatigue, and metabolic issues as willpower or diet failures. The microbiome research reframes them as a biological imbalance. This angle removes blame and replaces it with biology.
"The GLP-1 companion"
The Ozempic/Wegovy market is exploding. Users suffer GI side effects. Tiny Tribes' synbiotic stimulates natural GLP-1 production and supports the gut lining stressed by the drug. This is the highest-urgency angle in the deck — the audience is forming right now.
"Blood sugar starts in your gut"
Specific probiotic strains (L. plantarum, B. longum) measurably improve insulin sensitivity. This is peer-reviewed science, not biohacker speculation. Targets pre-diabetic and early T2D segments who are already glucose-aware.
"Ready for more than yoghurt?"
Direct gateway-brand bridge. Activia and Yakult have done the cultural work of teaching Europe that gut health matters. Tiny Tribes converts that broad audience into a specialist subscription.
"Test, don't guess"
Direct shot at greens powders, generalist multivitamins, and one-size-fits-all probiotics. Tiny Tribes Intelligence tier closes the loop with measurement. The frame: every other brand is asking you to take it on faith.
"Your inner home, in season"
The phase-rotation concept dramatised through the language of seasons. Spring = Foundation, Summer = Mediterranean, Autumn = Blueprint, Winter = Origin. Cinematic, beautiful, distinctly European — and the only narrative system in the category that justifies sustained subscription engagement.
A visual system as considered as the science.
Tiny Tribes dresses the science of the microbiome in the language of a serious European house. Editorial, restrained, warm — a brand that earns the premium price by feeling more like a small atelier than a supplement company.
Wordmark
Set in Fraunces italic — a contemporary serif with quiet warmth and editorial weight. Tracking is tightened on display sizes. Never abbreviated, never set in all caps in marketing, never paired with a tagline lockup. The logo carries the brand on its own.
Palette
#16140e
#2f4a35
#b8782f
#f4efe7
#d8e4d2
#a3391f
Dominant: Ink + Bone. Identity: Moss (the Tiny Tribes colour). Accents: Amber, Pale, Rust used sparingly. No purple, no neon, no gradients on white — explicit refusal of the AI-wellness cliché.
Typography
for considered display.